Secondary Hypogonadism: Rare and Atypical Presentations Clinicians Often Miss

What Defines Secondary Hypogonadism and Why Atypical Cases Get Missed

Secondary hypogonadism, also called hypogonadotropic hypogonadism (HH), means the gonads are structurally intact but deprived of adequate stimulation from LH and FSH. The hypothalamic-pituitary axis is the site of failure. Because serum LH and FSH may be low or simply "not elevated," many clinicians read the result as normal and stop there, missing the diagnosis entirely.

The Biochemical Trap

The core diagnostic error is interpreting an LH of 2 to 3 IU/L as acceptable when paired with a testosterone of 180 ng/dL. In primary hypogonadism, LH climbs above 10 IU/L to compensate. In secondary hypogonadism, the pituitary cannot mount that response. A 2018 Endocrine Society guideline states: "A low serum testosterone concentration should be confirmed by measuring LH and FSH to determine whether the hypogonadism is primary or secondary." [1]

The Problem with Population Prevalence Data

Reported rates of secondary hypogonadism in adult males hover around 2 to 4% of the general population, but this figure almost certainly underestimates functional forms driven by obesity and opioid use. A 2019 cross-sectional analysis in the Journal of Clinical Endocrinology and Metabolism (JCEM) estimated that functional HH secondary to obesity may affect 30 to 40% of severely obese men with low testosterone, the majority of whom go unclassified. [2]

Congenital Hypogonadotropic Hypogonadism: Beyond Kallmann Syndrome

Congenital hypogonadotropic hypogonadism (CHH) is the most well-defined rare presentation. Its prevalence is approximately 1 in 4,000 to 10,000 births, with a male-to-female ratio of roughly 3:1. Kallmann syndrome is the anosmia-associated subset, but CHH without anosmia (normosmic CHH) is just as common and far less likely to be recognized. [3]

Genetic Variants That Mislead Clinicians

Over 50 causative genes have been identified. The most clinically relevant include:

• ANOS1 (KAL1): X-linked, presents with synkinesia and renal agenesis alongside anosmia. Clinicians who do not ask about mirror hand movements miss the phenotype.
• FGFR1: Loss-of-function variants cause Kallmann syndrome type 2 with highly variable expressivity. A carrier father may have only partial GnRH deficiency and mild testosterone suppression, while his son has complete pubertal arrest. [4]
• GNRHR: Autosomal recessive mutations in the GnRH receptor gene cause normosmic CHH. LH pulse amplitude is absent on frequent sampling, but a single random LH may appear low-normal.
• PROKR2 and PROK2: Associated with sleep disorders and weight gain, leading to metabolic workups that miss the underlying neuroendocrine diagnosis.
• CHD7: Causes CHARGE syndrome (coloboma, heart defects, choanal atresia, growth retardation, genital abnormalities, ear anomalies). Hypogonadism in CHARGE patients is frequently attributed to the syndrome's systemic severity rather than investigated on its own terms.

Spontaneous reversal occurs in approximately 10 to 22% of CHH patients, according to a prospective cohort of 308 patients reported in the New England Journal of Medicine. [5] This means some patients placed on lifelong testosterone therapy could recover endogenous function if reassessed periodically.

Diagnosing CHH in the Absence of Puberty Clues

Adult men with CHH who were never evaluated during adolescence often present with infertility, small testicular volume (frequently below 4 mL), and erectile dysfunction. The absence of anosmia in normosmic CHH means the classic Kallmann trigger is never raised. Olfactory testing with a validated scratch-and-sniff tool should be performed in every male with suspected pituitary-axis hypogonadism before age 40. [3]

Drug-Induced Secondary Hypogonadism: The Reversible Forms Clinicians Overlook

Several medication classes suppress the HPG axis in ways that produce a secondary hypogonadism phenotype. This is the most correctable form, yet it is routinely misclassified as idiopathic or age-related.

Opioids

Opioids bind to mu-opioid receptors on hypothalamic GnRH neurons and suppress pulsatile GnRH release. A systematic review of 11 studies (N=1,642) published in Pain Medicine found that 21 to 86% of chronic opioid users had testosterone below the lower limit of normal, depending on opioid dose and duration. [6] Morphine-equivalent doses above 100 mg/day carry the highest risk. Fentanyl and methadone suppress testosterone more profoundly than buprenorphine, an important distinction for pain management teams.

Recovery after opioid cessation is inconsistent. One observational study reported that testosterone normalized in approximately 70% of patients within 3 to 6 months of cessation, but recovery may be incomplete in men who used opioids for more than 5 years. [6]

Glucocorticoids

Exogenous glucocorticoids suppress CRH and GnRH secretion directly and reduce LH pulse frequency. Prednisone at doses above 7.5 mg/day for more than 3 months measurably reduces testosterone in adult men. [7] Inhaled and intranasal corticosteroids at high doses (e.g., fluticasone 1,000 mcg/day) may also cause partial axis suppression, though the clinical effect is smaller and less consistent.

Anabolic-Androgenic Steroids

Exogenous androgens suppress LH and FSH to near-zero through negative feedback. Recovery of endogenous testosterone after cessation of anabolic steroid use is prolonged. A 2020 study in the Journal of Clinical Endocrinology and Metabolism followed 100 former users and found that 24% still had subnormal testosterone 24 months after stopping, meeting criteria for secondary hypogonadism rather than recovered function. [8] Clomiphene citrate 25 to 50 mg/day or human chorionic gonadotropin (hCG) 1,500 to 3,000 IU three times per week is used off-label to stimulate axis recovery, though FDA approval does not extend to this indication.

Antipsychotics and Prolactin-Elevating Agents

Dopamine D2 receptor antagonists (haloperidol, risperidone, metoclopramide) raise prolactin, which then suppresses GnRH pulsatility. Prolactin above 35 ng/mL in a male warrants repeat testing and pituitary MRI to differentiate drug effect from prolactinoma. Switching from risperidone to aripiprazole, a partial D2 agonist, normalizes prolactin in most patients within 4 to 8 weeks. [9]

Functional Hypogonadism: When the Axis Is Suppressed, Not Damaged

Functional hypogonadism (FH) is the most prevalent but least formally classified subtype. The Endocrine Society defines it as "hypogonadism resulting from reversible suppression of the HPG axis by conditions such as obesity, type 2 diabetes, critical illness, or nutritional deficit." [1] The gonads and pituitary are structurally intact; the axis is simply throttled.

Obesity-Related HPG Suppression

Adipose tissue aromatizes testosterone to estradiol, and elevated estradiol suppresses hypothalamic GnRH through negative feedback. Leptin resistance in severe obesity may also impair kisspeptin signaling, the upstream GnRH trigger. In a prospective study of 1,667 men in the European Male Aging Study, testosterone fell by 2.0 ng/dL for each unit increase in BMI above 25 kg/m², and LH did not compensate. [10]

Weight loss of 10% or more restores testosterone by an average of 2 to 3 ng/dL in most cohorts, making lifestyle intervention the first treatment step rather than testosterone replacement for men with BMI above 30 kg/m².

Type 2 Diabetes and Metabolic Syndrome

Insulin resistance independently suppresses GnRH pulsatility through mechanisms separate from adiposity. Men with type 2 diabetes have a two-fold higher prevalence of hypogonadism compared to metabolically healthy controls, with a predominantly secondary pattern. An American Diabetes Association position statement from 2021 recommended routine testosterone screening in symptomatic men with type 2 diabetes. [11]

Relative Energy Deficiency

Female athletes and military personnel on caloric restriction develop secondary amenorrhea as the sentinel sign of hypothalamic suppression. The Female Athlete Triad (low energy availability, menstrual dysfunction, low bone density) is a well-documented clinical syndrome, but the same physiology occurs in male endurance athletes with testosterone suppression and low LH. GnRH pulse testing distinguishes this from organic CHH when the history is unclear. [12]

Infiltrative and Inflammatory Causes: The Cases That Require MRI

Granulomatous and inflammatory diseases infiltrate the hypothalamus or pituitary stalk and disrupt GnRH transport or gonadotroph function. These cases rarely appear on standard differential lists and are frequently diagnosed late.

Sarcoidosis of the Hypothalamus

Central nervous system sarcoidosis affects approximately 5% of patients with systemic sarcoid, and hypothalamic involvement causes diabetes insipidus and hypogonadism as the most common neuroendocrine manifestations. A retrospective series of 49 patients with neurosarcoidosis published in Archives of Neurology found that 34% had at least one anterior pituitary hormone deficiency, with gonadotropin deficiency the most common. [13] The MRI finding is pituitary stalk thickening or a hypothalamic mass, not a classic pituitary adenoma.

Langerhans Cell Histiocytosis

LCH infiltrates the posterior pituitary stalk and hypothalamus with CD1a-positive dendritic cells. Diabetes insipidus presents first in most cases, but gonadotropin deficiency follows in roughly 40% of patients with hypothalamic LCH. Recognizing hypogonadism as an early sign of LCH in a young patient with polyuria prevents years of diagnostic delay. [13]

Hemochromatosis

Iron deposition in the pituitary preferentially damages gonadotrophs before other pituitary cell types. Serum ferritin above 1,000 ng/mL in a male with low testosterone and low LH should prompt hemochromatosis workup even without liver disease. A 2022 analysis in the British Medical Journal found that 30 to 40% of men with hereditary hemochromatosis and iron overload met biochemical criteria for secondary hypogonadism. [14] Phlebotomy-induced iron reduction partially restores gonadotropin secretion in approximately 50% of these patients if initiated before end-organ fibrosis.

Atypical Presentations in Women: Secondary Hypogonadism Is Not Just a Male Diagnosis

Most published data on secondary hypogonadism focus on men, but women develop the same spectrum of hypothalamic-pituitary failure with a different symptomatic profile. The absence of hot flashes, the hallmark of primary ovarian failure, frequently delays diagnosis.

Secondary Amenorrhea with Low-Normal FSH

Women with organic or functional HH have secondary amenorrhea but serum FSH that falls in the low-normal range (1 to 5 IU/L) rather than the elevated range seen in premature ovarian insufficiency. Clinicians who check FSH, see 3 IU/L, and reassure the patient are missing the diagnosis. Low estradiol alongside low-normal FSH is the correct pattern to flag. [1]

Hyperprolactinemia and Missed Microadenoma

A prolactinoma as small as 4 mm may produce prolactin levels of 60 to 100 ng/mL, enough to suppress GnRH and cause secondary amenorrhea and infertility without headache or visual field changes. Cabergoline 0.5 to 2 mg/week normalizes prolactin in more than 85% of patients with microprolactinoma, restoring ovulatory cycles without surgery. [15]

Postpartum Hypopituitarism (Sheehan Syndrome)

Sheehan syndrome results from ischemic pituitary necrosis after postpartum hemorrhage. Secondary hypogonadism is part of the panhypopituitary presentation, but in mild cases only gonadotropin deficiency manifests. Women who never resume menses after a complicated delivery should receive pituitary function testing within 6 months rather than waiting for other deficiencies to emerge. [15]

Diagnostic Framework for Rare and Atypical Secondary Hypogonadism

Standard biochemical evaluation covers total testosterone, free testosterone, LH, FSH, prolactin, and pituitary MRI when LH/FSH are low. The atypical cases require additional layers:

Step 1. Confirm the pattern. Total testosterone below 300 ng/dL in males or estradiol below 20 pg/mL in premenopausal females, paired with LH below 5 IU/L (or "not elevated" LH), defines the secondary pattern.

Step 2. Rule out drug causes. Obtain a full medication list including supplements and illicit substances. Opioid urine screen, anabolic steroid panel, and prolactin complete this layer.

Step 3. Assess functional drivers. Calculate BMI, HbA1c, serum ferritin, and review dietary intake. Energy restriction below 30 kcal/kg/day in athletes is a threshold for hypothalamic suppression.

Step 4. Order pituitary MRI with gadolinium. A normal MRI does not exclude CHH, neurosarcoidosis, or early LCH, but it identifies macroadenomas, stalk lesions, and structural abnormalities requiring neurosurgical consultation.

Step 5. Genetic testing in young patients. Males under 40 with organic HH and no identified pituitary lesion should receive a targeted gene panel covering ANOS1, FGFR1, GNRHR, PROKR2, PROK2, and CHD7. Pathogenic variants confirm CHH, guide family counseling, and clarify whether reversal testing is appropriate.

Step 6. Reversal testing at 12 to 24 months. For patients on testosterone replacement who may have CHH, a validated reversal protocol involves stopping testosterone, waiting 3 months for axis recovery, then measuring LH, FSH, and testosterone. Spontaneous LH rise above 4 IU/L with testosterone above 250 ng/dL constitutes partial reversal and warrants a trial of gonadotropin therapy if fertility is desired.

Treatment Principles Specific to Rare Presentations

Treatment selection differs substantially based on the underlying mechanism.

Gonadotropin Therapy for CHH and Fertility

Men with organic CHH who desire fertility should receive hCG 1,500 to 3,000 IU subcutaneously three times per week to restore intratesticular testosterone, combined with recombinant FSH (75 to 225 IU three times per week) to initiate spermatogenesis. JCEM data from a multicenter cohort show spermatogenesis is achieved in approximately 80% of CHH men within 12 to 24 months on combined gonadotropin therapy, with higher success rates in men whose testes measured above 4 mL at baseline. [16]

Addressing Reversible Causes Before Initiating TRT

Prescribing testosterone replacement to a man with opioid-induced hypogonadism without addressing opioid dose is a missed opportunity. A dose reduction to below 90 morphine-equivalent mg/day, with reassessment at 3 months, recovers testosterone without exogenous hormones in a meaningful proportion of patients. Coordinating with the prescribing pain specialist before starting TRT is a standard-of-care step that current guidelines endorse. [1]

Cabergoline First in Prolactinoma

The FDA-approved dopamine agonist cabergoline (Dostinex) suppresses prolactin more effectively than bromocriptine and restores gonadal function in most microprolactinoma patients without surgery. Starting dose is 0.25 mg twice weekly, titrated to normalize prolactin. Patients should be reassessed at 2 years for dose reduction trials; approximately 30 to 40% of microprolactinoma patients remain in remission after cabergoline discontinuation. [15]